BRAF and colorectal carcinoma: CMS-1 represents up to 15% of all CRC cases and is distinguished by microsatellite instability, high CIMP positivity, hypermethylation, and somatic copy number alterations (SCNA)-low, as well as BRAF and TGFBR2 mutations [72,73,74].